Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Codex DNA, Inc.
  6. Summary
    DNAY   US1920031010

CODEX DNA, INC.

(DNAY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
10.67(c) 10.8(c) 10.79(c) 10.64(c) 10.87(c) Last
21 435 54 657 39 074 35 503 45 764 Volume
+4.81% +1.22% -0.09% -1.39% +2.16% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 12,5 M - -
Net income 2021 -32,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,98x
Yield 2021 -
Sales 2022 20,6 M - -
Net income 2022 -42,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -7,65x
Yield 2022 -
Capitalization 318 M 318 M -
Capi. / Sales 2021 25,5x
Capi. / Sales 2022 15,4x
Nbr of Employees 108
Free-Float 47,3%
More Financials
Company
Codex DNA, Inc. is a synthetic biology company. The Company is focused on enabling researchers to build or write synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) that is ready to use in downstream synthetic biology enabled markets. Its synthetic biology solutions include the BioXp 3250 system, BioXp kits, BioXp portal, Benchtop reagent kits and Biofoundry services. Its BioXp system is an... 
More about the company
All news about CODEX DNA, INC.
09/20CODEX DNA, INC.(NASDAQGS : DNAY) added to S&P TMI Index
CI
09/16CODEX DNA : Departure of Directors or Certain Officers; Election of Directors; Appointment..
PU
09/16CODEX DNA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/16Codex DNA, Inc. Announces Departure of Timothy E. Cloutier as Senior Vice President, Ef..
CI
09/01Codex Dna Releases Full-Length Synthetic Genome for Highly Infectious Sars-Cov-2 Delta ..
CI
08/11CODEX DNA : Management's discussion and analysis of financial condition and results of ope..
AQ
08/10CODEX DNA : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
08/10CODEX DNA, INC. : Results of Operations and Financial Condition, Financial Statements and ..
AQ
08/10CODEX DNA : Earnings Flash (DNAY) CODEX DNA Reports Q2 Revenue $2.9M, vs. Street Est of $2..
MT
08/10CODEX DNA : Reports Second Quarter 2021 Financial Results
AQ
08/10Codex DNA, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Month..
CI
08/05Codex DNA Announces Synthetic Biology Collaboration with U.S. Department of Agriculture..
GL
08/03Codex DNA to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
GL
07/21CODEX DNA : Taps CleanCap mRNA Capping Technology From Maravai LifeSciences Unit TriLink
MT
07/21Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap..
AQ
More news
News in other languages on CODEX DNA, INC.

- No features available -

More news
Analyst Recommendations on CODEX DNA, INC.
More recommendations
Chart CODEX DNA, INC.
Duration : Period :
Codex DNA, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 10,87 $
Average target price 26,50 $
Spread / Average Target 144%
EPS Revisions
Managers and Directors
Todd R. Nelson President, Chief Executive Officer & Director
Jennifer Isacoff McNealey Chief Financial Officer
Daniel G. Gibson Chief Technology Officer
Justin O. Emory Vice President-Information Technology
Franklin R. Witney Independent Director
Sector and Competitors